Dr. Reddy's Labs launches bortezomib injection in US market
Dr. Reddy’s Laboratories Ltd announced the launch of bortezomib for injection 3.5 mg/vial, approved by the US Food and Drug Administration (FDA) via a 505(b)(2) new drug application (NDA) pathway for intravenous use only.
Dr. Reddy’s bortezomib for injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
“We are pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place,” explains Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the US market as we continue to augment our portfolio of products in the Hospital segment.”